# Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

> **NCT00664287** · PHASE3 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** niacin (+) laropiprant
- **DRUG:** placebo (unspecified)

## Key facts

- **NCT ID:** NCT00664287
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-09
- **Primary completion:** 2009-11
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00664287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00664287, "Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00664287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*